3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
2
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
Paclitaxel
177
Carboplatin
177
Bevacizumab
72
Topotecan
55
liposomal doxorubicin
54
Gemcitabine
53
Cisplatin
46
Docetaxel
39
Cyclophosphamide
37
olaparib
32
Filgrastim
31
pembrolizumab
29
Doxorubicin
26
niraparib
24
Taxes
23
Drug Therapy
23
Peripheral Blood Stem Cell Transplantation
20
Etoposide
17
veliparib
15
Nivolumab
14
sargramostim
13
Surveys and Questionnaires
13
Immunoglobulin G
13
Disulfides
13
pazopanib
12
Ifosfamide
12
Albumin-Bound Paclitaxel
12
durvalumab
11
atezolizumab
11
Trabectedin
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Ovarian Neoplasms
×
Technetium-99
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled